Protective roles of the fractalkine/CX3CL1-CX3CR1 interactions in alkali-induced corneal neovascularization through enhanced antiangiogenic factor expression

Journal of Immunology

Volumn 180, Issue 6, 2008, Pages 4283-4291

  Lu, Peirong ^a,b,c   Li, Longbiao ^b   Kuno, Kouji ^c   Wu, Yu ^c   Baba, Tomohisa ^c   Li, Ying Yi ^c   Zhang, Xueguang ^a   Mukaida, Naofumi ^c  

^a SOOCHOW UNIVERSITY   (China)

^b SUZHOU UNIVERSITY   (China)

^c KANAZAWA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALI; ANGIOGENESIS INHIBITOR; CHEMOKINE RECEPTOR CX3CR1; DISINTEGRIN; FRACTALKINE; MESSENGER RNA; METALLOPROTEINASE; PROTEIN ADAMTS 1; THROMBOSPONDIN 1; THROMBOSPONDIN 2; UNCLASSIFIED DRUG; VASCULOTROPIN; ADAM PROTEIN; ADAMTS1 PROTEIN, MOUSE; CHEMOKINE RECEPTOR; CX3CL1 PROTEIN, MOUSE; CX3CR1 PROTEIN, MOUSE; SODIUM HYDROXIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CORNEA INJURY; CORNEA NEOVASCULARIZATION; DRUG MECHANISM; GENE EXPRESSION; IMMUNOFLUORESCENCE; MACROPHAGE; MOUSE; NEUTROPHIL; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN ANALYSIS; WILD TYPE; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; CELL CULTURE; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; GENETICS; IMMUNOLOGY; MALE; METABOLISM; MONOCYTE; MOUSE MUTANT; PERITONEUM MACROPHAGE; PHYSIOLOGY; UPREGULATION;

ADAM PROTEINS; ALKALIES; ANGIOGENESIS INHIBITORS; ANIMALS; CELLS, CULTURED; CHEMOKINE CX3CL1; CORNEAL NEOVASCULARIZATION; MACROPHAGES, PERITONEAL; MALE; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; MONOCYTES; RECEPTORS, CHEMOKINE; SODIUM HYDROXIDE; THROMBOSPONDIN 1; UP-REGULATION;

EID: 44849088195     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.180.6.4283     Document Type: Article

References (62)

1. Chang, J. H., E. E. Gabison, T. Kato, and D. T. Azar. 2001. Corneal neovascularization. Curr. Opin. Ophthalmol. 12: 242-249.
2. Epstein, R. J., R. D. Stulting, R. L. Hendricks, and D. M. Harris. 1987. Corneal neovascularization: pathogenesis and inhibition. Cornea 6: 250-257.
3. Klintworth, G. K., and P. C. Burger. 1983. Neovascularization of the cornea: current concepts of its pathogenesis. Int. Ophthalmol. Clin. 23: 27-39.
4. Cursiefen, C., J. Cao, L. Chen, Y. Liu, K. Maruyama, D. Jackson, F. E. Kruse, S. J. Wiegand, M. R. Dana, and J. W. Streilein. 2004. Inhibition of hemangiogenesis and lymphangiogenesis after normal-risk corneal transplantation by neutralizing VEGF promotes graft survival. Invest. Ophthalmol. Visual Sci. 45: 2666-2673.
5. Streilein, J. W., J. Yamada, M. R. Dana, and B. R. Ksander. 1999. Anterior chamber-associated immune deviation, ocular immune privilege, and orthotopic corneal allografts. Transplant. Proc. 31: 1472-1475.
6. Dana, M. R., and J. W. Streilein. 1996. Loss and restoration of immune privilege in eyes with corneal neovascularization. Invest. Ophthalmol. Visual Sci. 37: 2485-2494.
7. Sano, Y., B. R. Ksander, and J. W. Streilein. 1995. Fate of orthotopic corneal allografts in eyes that cannot support anterior chamber-associated immune deviation induction. Invest. Ophthalmol. Visual Sci. 36: 2176-2185.
8. Streilein, J. W., D. Bradley, Y. Sano, and Y. Sonoda. 1996. Immunosuppressive properties of tissues obtained from eyes with experimentally manipulated corneas. Invest. Ophthalmol. Visual Sci. 37: 413-424.
9. Cursiefen, C., K. Maruyama, D. G. Jackson, J. W. Streilein, and F. E. Kruse. 2006. Time course of angiogenesis and lymphangiogenesis after brief corneal inflammation. Cornea 25: 443-447.
10. Lu, P., L. Li, N. Mukaida, and X. Zhang. 2007. Alkali-induced corneal neovascularization is independent of CXCR2-mediated neutrophil infiltration. Cornea 26: 199-206.
11. Zhou, J., L. Pham, N. Zhang, S. He, M. A. Gamulescu, C. Spee, S. J. Ryan, and D. R. Hinton. 2005. Neutrophils promote experimental choroidal neovascularization. Mol. Vis. 11: 414-424.
12. Tsutsumi-Miyahara, C., K. H. Sonoda, K. Egashira, M. Ishibashi, H. Qiao, T. Oshima, T. Murata, M. Miyazaki, I. F. Charo, S. Hamano, and T. Ishibashi. 2004. The relative contributions of each subset of ocular infiltrated cells in experimental choroidal neovascularisation. Br. J. Ophthalmol. 88: 1217-1222.
13. Taub, D. D. 1996. Chemokine-leukocyte interactions: the voodoo that they do so well. Cytokine Growth Factor Rev. 7: 355-376.
14. Sakurai, E., A. Anand, B. K. Ambati, N. van Rooijen, and J. Ambati. 2003. Macrophage depletion inhibits experimental choroidal neovascularization. Invest. Ophthalmol. Visual Sci. 44: 3578-3585.
15. Sakurai, E., H. Taguchi, A. Anand, B. K. Ambati, E. S. Gragoudas, J. W. Miller, A. P. Adamis, and J. Ambati. 2003. Targeted disruption of the CD18 or ICAM-1 gene inhibits choroidal neovascularization. Invest. Ophthalmol. Visual Sci. 44: 2743-2749.
16. Grossniklaus, H. E., J. X. Ling, T. M. Wallace, S. Dithmar, D. H. Lawson, C. Cohen, V. M. Elner, S. G. Elner, and P. Sternberg. 2002. Macrophage and retinal pigment epithelium expression of angiogenic cytokines in choroidal neovascularization. Mol. Vis. 21: 119-126.
17. Tsutsumi, C., K. H. Sonoda, K. Egashira, H. Qiao, T. Hisatomi, S. Nakao, M. Ishibashi, I. F. Charo, T. Sakamoto, T. Murata, and T. Ishibashi. 2003. The critical role of ocular-infiltrating macrophages in the development of choroidal neovascularization. J. Leukocyte Biol. 74: 25-32.
18. Ambati, B. K., A. M. Joussen, W. A. Kuziel, A. P. Adamis, and J. Ambati. 2003. Inhibition of corneal neovascularization by genetic ablation of CCR2. Cornea 22: 465-467.
19. Ambati, B. K., A. Anand, A. W. Joussen, W. A. Kuziel, A. P. Adamis, and J. Ambati. 2003. Sustained inhibition of corneal neovascularization by genetic ablation of CCR5. Invest. Ophthalmol. Visual Sci. 44: 590-593.
20. Ambati, J., A. Anand, S. Fernandez, E. Sakurai, B. C. Lynn, W. A. Kuziel, B. J. Rollins, and B. K. Ambati. 2003. An animal model of age-related macular degeneration in senescent Ccl-2- or Ccr-2-deficient mice. Nat. Med. 9: 1390-1397.
21. Apte, R. S., J. Richter, J. Herndon, and T. A. Ferguson. 2006. Macrophages inhibit neovascularization in a murine model of age-related macular degeneration. PLoS Med. 3: 1371-1381.
22. Furuichi, K., J. L. Gao, and P. M. Murphy. 2006. Chemokine receptor CX3CR1 regulates renal interstitial fibrosis after ischemia-reperfusion injury. Am. J. Pathol. 169: 372-387.
23. Barlic, J., Y. Zhang, J. F. Foley, and P. M. Murphy. 2006. Oxidized lipid-driven chemokine receptor switch, CCR2 to CX3CR1, mediates adhesion of human macrophages to coronary artery smooth muscle cells through a peroxisome proliferator-activated receptor γ-dependent pathway. Circulation 114: 807-819.
24. Imaizumi, T., H. Yoshida, and K. Satoh. 2004. Regulation of CX3CL1/fractalkine expression in endothelial cells. J. Atheroscler. Thromb. 11: 15-21.
25. Combadiere, C., S. Potteaux, J. L. Gao, B. Esposito, S. Casanova, E. J. Lee, P. Debre, A. Tedgui, P. M. Murphy, and Z. Mallat. 2003. Decreased atherosclerotic lesion formation in CX3CR1/apolipoprotein E double knockout mice. Circulation 107: 1009-1016.
26. Mantovani, A., A. Sica, S. Sozzani, P. Allavena, A. Vecchi, and M. Locati. 2004. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. 25: 677-686.
27. Landsman, L., C. Varol, and S. Jung. 2007. Distinct differentiation potential of blood monocyte subsets in the lung. J. Immunol. 178: 2000-2007.
28. Yrlid, U., C. D. Jenkins, and G. G. MacPherson. 2006. Relationships between distinct blood monocyte subsets and migrating intestinal lymph dendritic cells in vivo under steady-state conditions. J. Immunol. 176: 4155-4162.
29. Tacke, F., D. Alvarez, T. J. Kaplan, C. Jakubzick, R. Spanbroek, J. Llodra, A. Garin, J. Liu, M. Mack, N. van Rooijen, et al. 2007. Monocyte subsets differentially employ CCR2, CCR5, and CX3CR1 to accumulate within atherosclerotic plaques. J. Clin. Invest. 117: 185-194.
30. Geissmann, F., S. Jung, and D. R. Littman. 2003. Blood monocytes consist of two principal subsets with distinct migratory properties. Immunity 19: 71-82.
31. Yang, X., P. Lu, C. Fujii, Y. Nakamoto, J. L. Gao, S. Kaneko, P. M. Murphy, and N. Mukaida. Essential contribution of a chemokine, CCL3, and its receptor, CCR1, to hepatocellular carcinoma progression. Int. J. Cancer 118: 1869-1876.
32. Yang, X., P. Lu, Y. Ishida, W. A. Kuziel, C. Fujii, and N. Mukaida. 2006. Attenuated liver tumor formation in the absence of CCR2 with a concomitant reduction in the accumulation of hepatic stellate cells, macrophages and neovascularization. Int. J. Cancer 118: 335-345.
33. Oshima, T., K. H. Sonoda, C. Tsutsumi-Miyahara, H. Qiao, T. Hisatomi, S. Nakao, S. Hamano, K. Egashira, I. F. Charo, and T. Ishibashi. 2006. Analysis of corneal inflammation induced by cauterisation in CCR2 and MCP-1 knockout mice. Br. J. Ophthalmol. 90: 218-222.
34. Nakano, Y., T. Kasahara, N. Mukaida, Y. C. Ko, M. Nakano, and K. Matsushima. 1994. Protection against lethal bacterial infection in mice by monocyte-chemotactic and -activating factor. Infect. Immun. 62: 377-383.
35. Lu, P., Y. Nakamoto, Y. Nemoto-Sasaki, C. Fujii, H. Wang, M. Hashii, Y. Ohmoto, S. Kaneko, K. Kobayashi, and N. Mukaida. 2003. Potential interaction between CCR1 and its ligand, CCL3, induced by endogenously produced interleukin-1 in human hepatomas. Am. J. Pathol. 162: 1249-1258.
36. Espinosa-Heidmann, D. G., I. J. Suner, E. P. Hernandez, D. Monroy, K. G. Csaky, and S. W. Cousins. 2003. Macrophage depletion diminishes lesion size and severity in experimental choroidal neovascularization. Invest. Ophthalmol. Visual Sci. 44: 3586-3592.
37. Oh, H., H. Takagi, C. Takagi, K. Suzuma, A. Otani, K. Ishida, M. Matsumura, Y. Ogura, and Y. Honda. 1999. The potential angiogenic role of macrophages in the formation of choroidal neovascular membranes. Invest. Ophthalmol. Visual Sci. 40: 1891-1898.
38. Krampert, M., S. Kuenzle, S. N. Thai, N. Lee, M. L. Iruela-Arispe, and S. Werner. 2005. ADAMTS1 proteinase is up-regulated in wounded skin and regulates migration of fibroblasts and endothelial cells. J. Biol. Chem. 280: 23844-23852.
39. Benelli, R., A. Albini, and D. Noonan. 2003. Neutrophils and angiogenesis: potential initiators of the angiogenic cascade. Chem. Immunol. Allergy 83: 167-181.
40. Gaudry, M., O. Bregerie, V. Andrieu, J. El Benna, M. A. Pocidalo, and J. Hakim. 1997. Intracellular pool of vascular endothelial growth factor in human neutrophils. Blood 90: 4153-4161.
41. McCourt, M., J. H. Wang, S. Sookhai, and R. P. Redmond. 2001. Activated human neutrophils release hepatocyte growth factor/scatter factor. Eur. J. Surg. Oncol. 27: 396-403.
42. Ohki, Y., B. Heissig, Y. Sato, H. Akiyama, Z. Zhu, D. J. Hicklin, K. Shimada, H. Ogawa, H. Daida, K. Hattori, and A. Ohsaka. 2005. Granulocyte colony-stimulating factor promotes neovascularization by releasing vascular endothelial growth factor from neutrophils. FASEB J. 19: 2005-2007.
43. Morini, M., C. Tecchio, S. Minghelli, E. Di Carlo, E. Tanghetti, A. Albini, C. Lowell, G. Berton, D. M. Noonan, and M. A. Cassatella. 2004. CXCL1/ macrophage inflammatory protein-2-induced angiogenesis in vivo is mediated by neutrophil-derived vascular endothelial growth factor-A. J. Immunol. 172: 5034-5040.
44. Scapini, P., F. Calzetti, and M. A. Cassatella. 1999. On the detection of neutrophil-derived vascular endothelial growth factor (VEGF). J. Immunol. Methods 232: 121-129.
45. Liu, G. Y., V. Kulasingam, R. T. Alexander, N. Touret, A. M. Fong, D. D. Patel, and L. A. Robinson. 2005. Recycling of the membrane-anchored chemokine, CX3CL1. J. Biol. Chem. 280: 19858-19866.
46. Suzuki, F., T. Nanki, T. Imai, H. Kikuchi, S. Hirohata, H. Kohsaka, and N. Miyasaka. 2005. Inhibition of CX3CL1 (fractalkine) improves experimental autoimmune myositis in SJL/J mice. J. Immunol. 175: 6987-6996.
47. Nanki, T., Y. Urasaki, T. Imai, M. Nishimura, K. Muramoto, T. Kubota, and N. Miyasaka. 2004. Inhibition of fractalkine ameliorates murine collagen-induced arthritis. J. Immunol. 173: 7010-7016.
48. Cursiefen, C., S. Masli, T. F. Ng, M. R. Dana, P. Bornstein, J. Lawler, and J. W. Streilein. 2004. Roles of thrombospondin-1 and -2 in regulating corneal and iris angiogenesis. Invest. Ophthalmol. Visual Sci. 45: 1117-1124.
49. Gao, G., Y. Li, D. Zhang, S. Gee, C. Crosson, and J. Ma. 2001. Unbalanced expression of VEGF and PEDF in ischemia-induced retinal neovascularization. FEBS Lett. 489: 270-276.
50. Gao, G., and J. Ma. 2002. Tipping the balance for angiogenic disorders. Drug Discov. Today 7: 171-172.
51. Zhang, S. X., and J. X. Ma. 2007. Ocular neovascularization: implication of endogenous angiogenic inhibitors and potential therapy. Prog. Retin. Eye Res. 26: 1-37.
52. Dorrell, M. I., E. Aguilar, L. Scheppke, F. H. Barnett, and M. Friedlander. 2007. Combination angiostatic therapy completely inhibits ocular and tumor angiogenesis. Proc. Natl. Acad. Sci. USA 104: 967-972.
53. Ambati, B. K., M. Nozaki, N. Singh, A. Takeda, P. D. Jani, T. Suthar, R. J. C. Albuquerque, E. Richter, E. Sakurai, M. T. Newcomb, et al. 2006. Corneal avascularity is due to soluble VEGF receptor-1. Nature 443: 993-997.
54. Choudhary, A., P. Hiscott, C. A. Hart, S. B. Kaye, M. Batterbury, and I. Grierson. 2005. Suppression of thrombospondin 1 and 2 production by herpes simplex virus 1 infection in cultured keratocytes. Mol. Vis. 11: 163-168.
55. Uno, K., H. Hayashi, M. Kuroki, H. Uchida, Y. Yamauchi, M. Kuroki, and K. Oshima. 2004. Thrombospondin-1 accelerates wound healing of corneal epithelia. Biochem. Biophys. Res. Commun. 315: 928-934.
56. Uno, K., I. A. Bhutto, D. S. McLeod, C. Merges, and G. A. Lutty. 2006. Impaired expression of thrombospondin-1 in eyes with age related macular degeneration. Br. J. Ophthalmol. 90: 48-54.
57. Lee, N. V., M. Sato, D. S. Annis, J. A. Loo, L. Wu, D. F. Mosher, and M. L. Iruela-Arispe. 2006. ADAMTS1 mediates the release of antiangiogenic polypeptides from TSP1 and 2. EMBO J. 25: 5270-5283.
58. Yesner, L. M., H. Y. Huh, S. F. Pearce, and R. L. Silverstein. 1996. Regulation of monocyte CD36 and thrombospondin-1 expression by soluble mediators. Arterioscler. Thromb. Vasc. Biol. 16: 1019-1025.
59. Sekundo, W., A. J. Augustin, and I. Strempel. 2002. Topical allopurinol or corticosteroids and acetylcysteine in the early treatment of experimental corneal alkali burns: a pilot study. Eur. J. Ophthalmol. 12: 366-372.
60. Den, S., C. Sotozono, S. Kinoshita, and T. Ikeda. 2004. Efficacy of early systemic β-methasone or cyclosporin A after corneal alkali injury via inflammatory cytokine reduction. Acta Ophthalmol. Scand. 82: 195-199.
61. Chan, C. C., J. Tuo, C. M. Bojanowski, K. G. Csaky, and W. R. Green. 2005. Detection of CX3CR1 single nucleotide polymorphism and expression on archived eyes with age-related macular degeneration. Histol. Histopathol. 20: 857-863.
62. Tuo, J., B. C. Smith, C. M. Bojanowski, A. D. Meleth, I. Gery, K. G. Csaky, E. Y. Chew, and C. C. Chan. 2004. The involvement of sequence variation and expression of CX3CR1 in the pathogenesis of age-related macular degeneration. FASEB J. 18: 1297-1299.